PD-DigiCare: Enhancing referral decision-making for advanced treatment in Parkinson’s Disease through objective measurements and patient reported outcomes – a multicenter randomized controlled trial.
Objective: The overall aim is to compare the efficacy of using wearable devices versus standard of care in improving the timeliness of referrals to evaluation…Effect of Prasinezumab on Parkinson’s Disease Motor Progression in a Long-term Open-label Extension of the PASADENA Trial
Objective: To evaluate the long-term effect of prasinezumab on motor progression, assessed as change in MDS-UPDRS Part III in OFF- and ON-state, and MDS-UPDRS Part…Neurocognitive Functioning (NF) in a Patient with Idiopathic Parkinson’s Disease without Dementia (IPDWD). Subjected to Deep Brain Stimulation (DBS) and Treatment by Clinical, Functional and Advanced Neuropsychology.
Objective: To identify the Neurocognitive Functioning (NF) in a patient with IPDWD and intervened by DBS, and to analyze the impact of functional neurorehabilitation (FNR)…Blautia argi ameliorates the motor impairment of 6-Hydroxydopamine hydrochloride-induced Parkinson’s disease rat model
Objective: To evaluate the potential protective effects of Blautia argi on a 6-Hydroxydopamine (6-OHDA)-induced rat model of Parkinson's disease (PD). Background: PD is a common…A Quantitative Investigation has Revealed Nifedipine as a Possible Pharmacological Modulator in Parkinson’s Disease
Objective: Parkinson's Disease (PD) is strongly linked to atypical electrical firing patterns in the neuronal cells of the globus pallidus externus (GPe), hence highlighting the…Baseline Variables Associated with Apomorphine Sublingual Film Retention
Objective: The aim of this analysis was to identify the baseline variables that differ between patients who completed Study CTH-301 and those who discontinued during…Opicapone real-world experience in early motor fluctuations: 3-months analysis of the REONPARK study.
Objective: The REONPARK study aims to evaluate COMT inhibitor (iCOMT) effectiveness and tolerability in alleviating motor complications associated with L-dopa treatment in Parkinson’s Disease patients…One dose fits all? An analysis of the levodopa equivalent dose over time in Parkinson’s disease
Objective: To ascertain and delineate the differences in Levodopa Equivalent Dose (LEDD) among Parkinson’s disease (PD) subtypes and to examine its evolution over the disease’s…The impact of long-term continuous subcutaneous apomorphine infusion on the reduction of remaining medications in levodopa equivalent dosage and on increasing plasma vitamin B12 levels in patients with advanced Parkinson’s disease
Objective: To evaluate the plasma levels of vitamin B and homocysteine among 28 advanced PD patients with motor complications before and after continued used of…Pathological Mechanisms Associated with Atrazine-Induced Parkinson’s Disease Pathogenesis in Rat Model: The Rescue Role of Myricetin
Objective: This study aimed at investigating the mechanisms involved in the pathogenesis of Parkinson’s Disease in atrazine rat model of Parkinson’s Disease and the neuroprotective…
- « Previous Page
- 1
- …
- 144
- 145
- 146
- 147
- 148
- …
- 181
- Next Page »